MiMedx Stock Could Rip +100% In Coming Months
Investors are expecting big things in MiMedx which is why growth is not cheap. The forward P/E is 33.6, the PEG is 6.35, and the P/S is 7.26. Still, revenue growth over the last 4 years has been shocking.
In 2011, revenue was $7.8 million. In 2014, revenue had grown to $118.2 million. That’s more than a +1,500% increase in revenue over the last 4 years.
The last quarterly earnings report was awesome from a growth perspective.
Highlights from the first quarter 2015 report:
Q1 2015 revenue of $40.8 million increases 108% over Q1 2014
Q1 2015 is 14th consecutive quarter of meeting or exceeding revenue guidance
Q1 2015 Wound Care sales grows 103% over Q1 2014
Q1 2015 Surgical, Sports Medicine/Orthopedic revenue increases 125% over Q1 2014
Adjusted EBITDA of $8.8 million represents a 343% improvement over Q1 2014
Quarterly net income of $4.1 million or $0.04 per diluted share vs a net loss of $900,000 or $0.01 per diluted share in Q1 2014
Q1 2015 Cash Flow from Operating Activities of $4.2 million as compared to a negative $1.6 million in Q1 2014
Company increases full year guidance range from $175-$190 million to $180-$190 million
Significant progress made during quarter in gaining coverage from commercial as well as Medicaid payers
Company signs new building lease adding approximately 25,000 sq. ft. of space in support of planned growth
The chart of MiMedx shows the stock is in a Symmetrical Triangle (purple) pattern which is a consolidation pattern. The stock has yet to trigger a Parabolic SAR buy signal which would make an excellent entry imo.
Source: guerillastocktrading.com/stocks/mimedx-stock-high-risk-high-reward-play-could-soar-200/
In 2011, revenue was $7.8 million. In 2014, revenue had grown to $118.2 million. That’s more than a +1,500% increase in revenue over the last 4 years.
The last quarterly earnings report was awesome from a growth perspective.
Highlights from the first quarter 2015 report:
Q1 2015 revenue of $40.8 million increases 108% over Q1 2014
Q1 2015 is 14th consecutive quarter of meeting or exceeding revenue guidance
Q1 2015 Wound Care sales grows 103% over Q1 2014
Q1 2015 Surgical, Sports Medicine/Orthopedic revenue increases 125% over Q1 2014
Adjusted EBITDA of $8.8 million represents a 343% improvement over Q1 2014
Quarterly net income of $4.1 million or $0.04 per diluted share vs a net loss of $900,000 or $0.01 per diluted share in Q1 2014
Q1 2015 Cash Flow from Operating Activities of $4.2 million as compared to a negative $1.6 million in Q1 2014
Company increases full year guidance range from $175-$190 million to $180-$190 million
Significant progress made during quarter in gaining coverage from commercial as well as Medicaid payers
Company signs new building lease adding approximately 25,000 sq. ft. of space in support of planned growth
The chart of MiMedx shows the stock is in a Symmetrical Triangle (purple) pattern which is a consolidation pattern. The stock has yet to trigger a Parabolic SAR buy signal which would make an excellent entry imo.
Source: guerillastocktrading.com/stocks/mimedx-stock-high-risk-high-reward-play-could-soar-200/
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.